US Biopharmaceuticals Market 2026 – 2035

The market size of US biopharmaceuticals is estimated at USD 169.45 billion in 2025 and is estimated to grow between USD 185.21 billion in 2026 and USD 630.60 billion in 2035 and will grow by the CAGR of 14.55% between 2026 and 2035.

The rise in the number of chronic diseases, the demographics of the aging population, high research and development, a good regulatory climate, increased use of personalized medicine, and technological innovation in the production of biologics are motivating factors for the market growth.

Market Highlight

• The US market shares a single country market of about 46% of the total global biopharmaceuticals market in 2025, the largest in the world.

• By product type, the monoclonal antibodies segment is expected to capture 38% of the market share in 2025.

• By product line, the cell and gene therapies division is projected to have the highest growth rate of 18.2% between 2026 and 2035.

• The oncology segment is the largest market share with 31% in 2025 and the autoimmune disorders segment is projected to have a CAGR of 16.5%, with the projected market growth existing between 2026 and 2035.

• By type of drug, proprietary branded drugs took 77.9% of the market share in the year 2025, and biosimilars have the largest increase in the rate at 19.8% CAGR.

• The biopharmaceutical sector directly employed more than 1.05 million people in the US in 2022, an industry contributing to over 4.9 million jobs in the total economy.

Significant Growth Factors

The US Biopharmaceuticals Market Trends present significant growth opportunities due to several factors:

• Escalating Chronic Disease Burden and Aging Population Demographics:

The main forces of the US biopharmaceuticals market are the growing cases of chronic diseases and the ageing population that rapidly grows, and millions of Americans need sophisticated therapeutic interventions, which can be offered by biologics only. The Centers for Disease Control and Prevention (2023) state that in 2023, about 76.4% of all adults in the US had at least one long-term health condition, indicating over 190 million adults in need of constant medical care. The American Cancer Society forecasted 1.95 million new cancer cases in the United States in 2023, making the need for treatments in oncology crucial, with biologics being a common component of them.

The 2021 statistics on heart disease and stroke released by the American Heart Association note that cardiovascular disease is the number one cause of death, with 17.9 million deaths in the United States alone and 40.3% of the total deaths in the country, which includes heart disease and stroke. There is also the increasing weight of metabolic illnesses, which are being met with more than 537 million individuals having been diagnosed with diabetes around the world and about 60% of the American population having at least one chronic illness, demanding unprecedented biopharmaceutical measures. This demand is enhanced by the aging population since the population of people aged 60 and above worldwide is projected by the World Health Organization to increase to 1.4 billion by 2030, with this group of individuals being the main victims of age-related illnesses such as Alzheimer's disease, Parkinson's disease, and other cancers that have biopharmaceutical treatment solutions. It is expected that the prevalence of Alzheimer's disease will reach as much as 78 million in 2030 and 139 million in 2050, leading to the development of disease-modifying therapies, like monoclonal antibodies like Leqembi (lecanemab-irmb), which was approved by the FDA in January 2023 as a treatment for early-stage Alzheimer's disease, reducing amyloid-2 plaques and slowing the progression of the illness at a moderate rate.

The annual prevalence of autoimmune diseases has been growing between 3 and 9%, and the current number of affected individuals worldwide is more than 20 million, with rheumatoid arthritis and multiple sclerosis among the most common ones that require more sophisticated biopharmaceutical treatment. The growing prevalence of such complicated, chronic diseases, which are not efficiently addressed using traditional small-molecule drugs, leaves an enduring demand of biologics which provide specific and an individual approach to treatment with enhanced efficacy and fewer side effects than conventional treatments.

• Robust Research and Development Investment and Innovation Leadership:

The dedication of the US biopharmaceutical sector to research and development is a core growth driver, and pharmaceutical companies in 2023 spend about $96 billion on research and development work, according to the Pharmaceutical Research and Manufacturers Association (PhRMA), which is more than 20% of total sales and indicates the innovation-based business model of such a sector. This heavy investment in R&D which has been estimated to cost over 200 billion dollars a year in the industry at large drives the development of an unending pipeline of innovative biopharmaceutical treatments to unmet medical demands in various therapeutic sectors. The United States is a world leader in the innovation of biopharmaceuticals, with 55 new drugs and 17 new biologics (30 of all new drugs) being approved by the FDA in 2023, as the biological therapeutics are increasingly becoming a significant part of modern medicine.

The Center for Biologics Evaluation and Research (CBER) may have added 23 new biologics license application approvals in 2023, demonstrating lasting regulatory support for novel therapies. In 2024 the Food and Drug Administration (FDA) approved seven new cell and gene therapy products (including the first cellular therapy for solid tumors), representing "first-of-a-kind" approvals related to novel and highly-targeted therapies marking the ambitious industry shift toward developing bespoke therapies, moving past one-size-fits-all treatments. Such approvals are for groundbreaking treatments like Vertex and Exa-cel (Casgevy) by CRISPR, a single-time gene therapy that treats sickle cell disease and beta-thalassemia and that was approved by the FDA, and Dupixent by Regeneron and Sanofi with good efficacy in treating COPD, which established new benchmarks in respiratory medicine. As of 2022, 40 biosimilars are approved by the FDA among 17 distinct reference products, which increases access to treatment and leads to care cost management without impairing therapeutic effectiveness.

The recent scientific discoveries in biotechnology such as CRISPR gene editing, monoclonal antibody development, recombinant DNA technology, and mRNA platforms are transforming the development of drugs, allowing the development of more specific and effective interventions with superior accuracy and less off-target toxicity. In the case of monoclonal antibodies alone, the market size was expected to be more than $300 billion by 2025, due to increasing use of biopharmaceuticals in the treatment of oncology, immunology, and infectious disease uses. Drug discovery, bioprocess optimization, and personalized medicine Investment in artificial intelligence and machine learning is enhancing the effectiveness of R&D and reducing both the costs and the time-to-market of new therapies, and the AI in biopharmaceuticals market is expected to reach 24.49 billion dollars by 2034, at a 32.27% CAGR. The partnerships between biopharmaceutical firms and academic organizations have enabled the creation of conducive conditions to conduct groundbreaking research and the National Institutes of Health spend much money in funding biomedical research in the country.

What are the Major Advances Changing the US Biopharmaceuticals Market Today?

• Personalized Medicine and Precision Therapeutics Revolution:

The shift to the personalized medicine paradigm is the biggest change in the development of biopharmaceuticals because the treatment is becoming more individualized based on the genetic profile of the particular patient, expression of biomarkers, and disease features, thus improving treatment efficacy with reduced toxicity. The market of personalized medicine is set to grow to 2 trillion by 2025, which means that the demand for biopharmaceuticals tailored for the needs of particular patients and their genetic differences is high. This tendency pushes the biopharmaceutical companies to invest enormous sums into the genomic studies and biomarker discovery and leads to innovation in the area of companion diagnostics that are able to determine which patients will respond best to certain treatment. State-of-the-art genetic engineering tools, high-throughput screening systems, and next-generation sequencing technologies allow a more detailed molecular-level insight into the pathogenesis of diseases and allow creating targeted therapies, targeting the root causes, rather than treating the symptoms.

The incorporation of pharmacogenomics permits the forecasting of the patient reactions to certain biopharmaceuticals basing on genetic differences, ensuring accurate dosing and selection of treatment, which upsurpasses the efficacy rates and minimizes the occurrence of toxicity. The FDA regulatory efforts that are creating the regulatory environment to address personalized medicine development via any of the expedited approval processes of breakthrough treatments and companion diagnostics foster faster market access of novel precision therapeutic products.

The adoption of personalized medicine is led by oncology, and targeted therapies such as Keytruda and Opdivo are recording remarkable increments in year-on-year sales since they are able to identify and target certain tumor properties by targeting the PD-1/PD-L1 pathways. Immunotherapy methods, such as CAR T-cell therapies, entail ultimate personalization, in which patients' own immune cells are programmed to hunt down specific cancer antigens to attain impressive remission rates in previously incurable malignancies such as acute lymphoblastic leukemia and multiple myeloma. Personalized approaches are becoming more and more a feature of the development of disease-modifying therapies for neurodegenerative disorders, cardiovascular diseases and rare genetic conditions, where the development of the treatment is guided by the pathophysiology of the individual patient as opposed to population-based averages.

• Biosimilars Market Expansion and Healthcare Cost Management:

The biosimilars boom is a revolutionary development in the US biopharmaceuticals industry, fueled by the expiry of patents on blockbuster biologics, regulatory decisions allowing new drugs to enter the market, and the healthcare system focusing on spending less and more on the cost of providing patients access to essential treatments. By the year 2024, 63 biosimilars containing 17 unique reference products were approved by the FDA and more are bound to be approved as more patents expire throughout the forecast period. In the United States, biosimilars saved the healthcare sector about 7 billion dollars in 2021, and governments and payers actively promote the prescription and dispensing of biosimilars in order to lower the total healthcare expenditure at the same time as maintaining the therapeutic efficacy of reference biologics.

The biosimilars market is growing at the quickest rate, with a growing number of blockbuster bio-pharmaceuticals with billion dollar yearly values, giving rise to biosimilars producers as a possibility to market their goods by following compensation policies of 15-35% below the reference products. The major market front runners are taking advantage of biosimilar demand by pursuing regulatory approvals of biosimilar drug candidates in therapeutic areas such as oncology, immunology and endocrinology. As an example, in May 2024, Yesafili, an aflibercept biosimilar therapeutically used as a VEGF inhibitor in the treatment of several ophthalmic conditions, such as age-related macular degeneration, was approved by the US FDA by Biocon Biologics. Accord BioPharma in October 2024 received FDA approval of IMULDOSA (ustekinumab-srlf), a biosimilar of STELAR in treating chronic inflammatory diseases, such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, and planned commercial introduction in the first half of 2025.

The introduction of anti-TNF product biosimilars in the US has led to a reduction in average prices, which increases access to patients with autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease, and ankylosing spondylitis. The manufacturers of biosimilars enjoy shorter regulatory processes that prove the biosimilarity between two compounds by conducting comparative analytical, preclinical, and clinical testing instead of developing products by full development programs, thereby saving time and costs incurred on the market introduction of the products. The FDA maintains a database of approved biosimilars and interchangeable biologics in the Purple Book which makes informed prescribing decisions by healthcare professionals and promotes biosimilar adoption.

• Advanced Cell and Gene Therapy Technologies:

The concept of cell and gene therapies has been revolutionary treatment modalities to treat previously incurable diseases by going through genetic modification/cellular engineering procedures, and so this segment is the quickest growing at 18.2% CAGR between 2026 and 2035. This rehabilitative potential of innovative treatment and the control of the regulation of tools at the high-level manufacturing and commercialization can be illustrated by the fact that the FDA has approved 7 new cell and gene therapy products in 2024, including the first cellular therapy for solid tumors. CAR T-cell therapies have been an incredible success in the treatment of hematologic malignancies; products such as Kymriah (tisagenleucel) and Yescarta (axicabtagene ciloleucel) have shown never-before-seen remission rates in patients with relapsed or refractory acute lymphoblastic leukemia and large B-cell lymphomas who had previously tried and failed all the conventional treatment modalities.

The genetic disorders are being treated at the root cause by the use of gene therapy methods that involve the introduction of a working copy of the gene, gene editing with CRISPR-Cas9 technology, or gene silencing methods. The first CRISPR-based gene therapy approved by the FDA is Vertex and CRISPR Therapeutics Casgevy (exagamglogene autotemcel), which provides a one-time cure of sickle cell disease and beta-thalassemia by CRISPR-based ex vivo gene editing of the hematopoietic stem cells of patients. The 2022 FDA approval of SKYSONA (elivaldogene autotemcel) by Bluebird Bio, to slow neurologic progression in boys with early and active cerebral adrenoleukodystrophy (age 4-17 years), is evidence of the potential of gene therapy in very rare pediatric diseases with a limited treatment profile. Lentiviral and adeno-associated viral vectors are now capable of efficient delivery of genes to target cells and current research efforts focus on better designs of vectors, improved transduction efficiency, decreased immunogenicity and increased tissue tropism.

The next frontier is the creation of in vivo gene therapies directly transferred to patients, which could eliminate complicated ex vivo cell processing possibly and increase access to treatments. The production capacities in the field of cell and gene therapies are quickly evolving, and specialized contract development and manufacturing organizations (CDMOs) have built specialized facilities that promote the generation of personalised cellular therapies on a commercial scale. Although the cost of cell and gene therapies currently ranges between $400,000 and over $2 million per treatment, the cell and gene therapies have the potential of providing one treatment instead of managing a chronic condition, which is worth the short-term investment in treatment costs in terms of long-term savings in healthcare expenses and enhanced patient lifespan.

• Monoclonal Antibody Engineering and Next-Generation Formats:

Monoclonal antibodies will remain the market leader preserving 38% of market share in 2025, and the constant innovation in the field of antibody engineering, formatting, and conjugation is increasing the use of antibodies in therapy and enhancing clinical outcomes in a wide variety of diseases. The monoclonal antibodies segment has the advantages of high specificity to disease causing antigens, longer half-lives to allow convenient dosage regimens, fewer side effects than classical chemotherapies, and more FDA approvals to support market growth. Sophisticated antibody engineering methods such as humanization, affinity maturation and glycoengineering increase therapeutic characteristics, minimizing the risk of immunogenicity and maximizing efficacy and PK characteristics. Newer forms of antibodies such as bispecific antibodies, antibody-drug conjugates (ADCs), and antibody fragments, have superior functionality over traditional monoclonal antibodies.

Bispecific antibodies are those that specifically target two antigens or epitopes simultaneously and are used in novel ways of action, such as in redirecting T-cells to tumor cells, dual pathway blockade, or receptor clustering, with products such as epcoritamab (Epkinly/Tepkinly) being approved by the FDA and EMA to treat relapsed or refractory large B-cell lymphoma. Antibody-drug conjugates are immunologic biomolecules with specificity and potency of cytotoxics that activate chemotherapy to cancer cells without including normal tissues to revolutionize oncology therapy, such as Kadcyla (trastuzumab emtansine) and Enhertu (trastuzumab deruxtecan), which have shown improved efficacy in cancer treatment in HER2-positive breast cancer. In October 2022, the FDA approved PT217, a bispecific anti-DLL3/anti-CD47 antibody developed by Phanes Therapeutics, which is used in the treatment of small cell lung cancer, which is an example of innovative technologies that use immune systems to help the patient with aggressive malignancies. Modification of Fc engineering functions to augment antibody effector functions such as antibody-dependent cellular cytotoxicity (ADDC), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP) has been shown to enhance therapeutic efficacy on cancer and infectious disease antigens.

Category Wise Insights

By Product Type

Why Monoclonal Antibodies Lead the Market?

The highest share is occupied by monoclonal antibodies in 2025; the market share will reach about 38. This hegemony is demonstrative of the unprecedented therapeutic versatility of monoclonal antibodies, their high efficacy in a wide range of disease targets, and their innovation that has led to ever-expanding clinical use. Monoclonal antibodies prevail because of their highly specific therapeutic properties and wide stages of use in all types of diseases, such as cancer, autoimmune diseases, and infectious diseases. Such modified antibodies target certain antigens found on cell surfaces (or circulated in biological fluids), which facilitates specific targeting of the target, increasing efficacy and reducing off-target effects typical of small-molecule drugs. Their capacity to be adapted to particular molecular targets and good pharmacokinetic characteristics such as longer half-lives that allow patients to take drugs conveniently, contribute to their large market share of tens of billions of dollars per year.

The disease most treated with monoclonal antibodies is cancer, and immune checkpoint inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), have transformed the paradigm of cancer treatment by means of activating the immune response of the patients against cancer. The FDA data reveals that about 9 monoclonal antibodies are approved each year with 2023 being the second-highest year of mAb approvals. The FDA approved 13 mAbs out of 16 total biologics in 2024 and this shows that the regulatory body continuously supports and the market needs biologics. The ongoing flood of approvals of mAbs in a variety of conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease as well as a number of cancers are additional stimuli to market growth. The new generation development of monoclonal antibodies involves newer engineering methods such as humanization which lowers immunogenicity, affinity maturation, which increases binding affinity and Fc modifications which amplify effector activities, to form the next-generation therapeutics with better clinical characteristics.

The most rapid expansion is in cell and gene therapies with a projected CAGR of 18.2% between 2026 and 2035 due to the revolutionary potential of these therapies in terms of treatment of diseases that used to be incurable and the increasing number of regulations to permit these types of therapies. The fact that the FDA has approved seven new cell and gene therapy products in 2024, and one of them is the first cellular therapy for solid tumors, shows how transformative these innovative modalities are. CAR T -Cell therapies have been remarkably successful in hematologic malignancies, and the products have shown superior remission rates in patients who had depleted conventional therapies. Gene therapies also treat genetic defects at etiology by inserting functional genes, editing using CRISPR, or silencing genes, and provide one-time potential cures as opposed to managing chronic disease. The fact that Casgevy has passed the clinical trial test on the treatment of sickle cell disease and beta-thalassemia is a milestone that confirms gene editing as a correct therapeutic option.

By Therapeutic Application

Why Oncology Dominates Biopharmaceutical Applications?

The largest market is oncology applications, which is estimated to get about 31% total market share in 2025. This leadership points towards the basic importance of biopharmaceuticals in the treatment of cancer with the agents of targeted biologics having transformed the treatment methods with significant improvements in the survival and quality of life of patients, as compared to the conventional chemotherapy method. In the United States alone, the American Cancer Society estimated that 1.95 million new cancer cases would be diagnosed in 2023 with cancer being the second leading cause of death both locally and around the world.

The World Health Organization estimates that in 2022, about 20 million cancer incidences and 9.7 million cancer deaths were noted worldwide, with cancer being the second leading cause of death in 2020, and thus resulting in about 9.6 million cancer deaths in 2020 worldwide. The growing worldwide cancer load, combined with robust clinical development of targeted biologic and immunotherapeutic agents, creates an ensuing market growth in the oncology markets. Oncology segment is amongst the most dynamic and fast developing sectors of biopharmaceutical industry and is driven by the growing prevalence of cancer across the globe and the progressive development of the cancer treatment procedures. Oncology Biopharmaceutical innovations include monoclonal antibodies that bind tumor-associated antigens, immune checkpoint inhibitors that release immune system anti-tumor responses, antibody-drug conjugates that deliver cytotoxic things to cancer cells specifically, CAR T-cell therapies that engineer immune cells of the patient to recognize cancer antigens, and bispecific antibodies, which combine immunological cell types and tumor targets. These targeted therapies offer improved and customized treatment options over the traditional chemotherapeutics, and since they have improved efficacy profiles and lower systemic toxicity, they can be better tolerated by the patient and have better outcomes. Breast, lung, prostate and colorectal cancers are also among some of the most commonly diagnosed malignancies with several formidable biopharmaceutical treatment options such as trastuzumab against HER2-positive breast cancer, pembrolizumab against non-small cell lung cancer andPD-L1 expression, and bevacizumab against metastatic colon cancer.

Autoimmune disorders are growing fastest with a predicted CAGR of 16.5% between 2026 and 2035 due to rising disease prevalence, growing knowledge on immunologic processes, and emergence of new biologics that have better efficacy and fewer side effects than traditional immunosuppressants. The prevalence of autoimmune diseases is on the rise by a range of 3 to 9% annually with more than 20 million individuals worldwide being affected by the likes of rheumatoid arthritis, inflammatory bowel disease, psoriasis, multiple sclerosis, and systemic lupus erythematosus. New biopharmaceuticals that address particular immune pathways such as TNF- alpha, IL-17, B-cell, and co-stimulation are the drugs that have revolutionized the management of autoimmune diseases and have helped management to achieve disease remission instead of the control of symptoms. The evolving innovation on autoimmune disorder therapy, though, is illustrated by the European Commission approval of BRIUMVI (ublituximab-xiiy) in June 2023 as a treatment of relapsing forms of multiple sclerosis.

By Drug Type

Why Proprietary Branded Drugs Dominate the Market?

Proprietary branded biopharmaceuticals are the most significant category with about 77.9% of the market in 2025. This leadership is indicative of heavy investments in R&D, patent protection that gives the company an edge in the market, ongoing innovations in biologics, and high pricing based on the clinical value given out by advanced treatment standards. They are patented drugs sold under proprietary names and deal with various life-threatening healthcare complications of cancer, cardiovascular, neurologic, immunological, and other illnesses. Premium pricing strategies to promote future innovation are justified by high R&D investments which sometimes run in the billions of dollars to support one successful drug, and a comprehensive clinical trial program indicating safety and efficacy. Patent protection usually grants 12-20 years of exclusiveness in the market from its filing date, which allows companies that originated the patent to recover their development expenses and invest in future research before the appearance of biosimilar competitors. Examples of proprietary branded biopharmaceuticals are blockbuster products, including Keytruda (pembrolizumab), which had sales of more than 20 billion per annum, Humira (adalimumab) with a historical track record of over 20 billion sales in the past; and Dupixent (dupilumab), which is rapidly growing in several indications. The high cost of the branded biopharmaceuticals is indicative of various factors such as high innovation capital, clinical worth in terms of better patient outcomes, specialized production needs, and the patent cover in order to recover its costs.

Biosimilars are the most rapidly growing market, with a prognosticated CAGR of 19.8 in 2026-2035 due to the rising numbers of blockbuster biologic patent expiries, regulatory authorizations to enter the market, lower prices, aiming at enhancing the accessibility of medicines to patients, and pressure by payers to ease spending on health techniques. As of 2024, the FDA has authorized 63 biosimilars related to 17 separate reference products, and this figure is likely to increase significantly as more patents expire. In the United States, it is estimated that biosimilars saved healthcare around 7 billion dollars in 2021, which shows that the economic effect of such products is quite significant due to the implemented competitive pricing strategies with 15-35% discounts relative to reference biologics and the same therapeutic effect. The FDA maintains the Purple Book database that offers transparency on approved biosimilars and interchangeable biologics and can inform prescribing and ease biosimilar adoption in healthcare systems.

Report Scope

Economic Impact Analysis

How Significant is the Industry's Economic Contribution?

The US biopharmaceutical sector is an important sector of the economy that contributes greatly to the GDP, employment and balance of trade of a country. In 2022, the biopharmaceutical sector produced more than 800 billion dollars of direct output, which directly contributed to the US GDP 1.6% with other economic activity along supply chains contributing to 850 billion dollars or 3.4% of US GDP. The pharmaceutical manufacturing industry has a value added output of 355 billion to the US economy in 2021 with the direct contribution of 192 billion being 24% growth in two years, indicating the growing economic relevance of the sector. Since the employment multiplier in the industry is high at 4.69, one direct biopharmaceutical job would benefit 4.69 other jobs in the economy in both supplier industries, distribution networks, and service industries.

The biopharmaceutical industry directly employed over 1.05 million workers in 2022, this direct employment contributing to employment of over 3.8 million more workers in total employment impacting over 4.9 million jobs in the US economy. Biopharmaceutical R&D employment has grown significantly in 2015-2022, showing growth of 30.85% that has endured economic recessions, including the 2020 pandemic, and offers meaningful stability to life medicine manufacturing as well as economic success. Bio manufacturing of pharmaceuticals occupies 34% of the employment in the industry, with biopharmaceutical distribution having an occupation of almost 248,374 jobs at 248,000, and other biopharmaceutical corporate offices employment taking over other positions. The biopharmaceutical industry offers salaries and benefits that are very high and the average earnings per employee per year are more than 157, 000 dollars well above the average wages of a manufacturing position and the positions in the industry are very skilled and well-educated.

What is the Industry's Trade and Manufacturing Impact?

Biopharmaceutical industry has a great manufacturing presence in the United States, where Pharmaceutical Preparation Manufacturing subsector had sales of approximately 154.7 billion, shipments of 154.7 billion or revenue of 46.8 billion in 2020, and Biological Product Manufacturing had sales of 46.8 billion. The Biopharmaceuticals industry directly employs more than 224,000 individuals in the manufacturing sector and the annual payroll amounted to about 21.2 billion in 2020. The industry is highly productive, as shown by the industry employees generating an output of 1.2 million per employee which is almost half a dozen times greater than the average output per employee in the US economy of 208,084, due to the nature of biopharmaceutical products and the extended manufacturing process involved.

In 2023, foreign direct investment in pharmaceuticals and medicines was recorded at a value of 503.4 billion and the inward position of FDI was recorded at 545.5 billion, and this indicates international confidence in the strength and attractiveness of the US biopharmaceutical industry in the allocation of global capital. Over 25 billion of biopharmaceutical exports were due to a majority of foreign-owned companies involved in the United States, which offset the trade balance in a positive way, and these same companies invested almost 26 billion in domestic R&D activities. The export business of the biopharmaceutical industry helps to enhance the national presence in the international markets with drugs, vaccines, and medical device exports, helping to reduce the trade deficits.

Top Players in the Market

• Pfizer Inc.

• Johnson & Johnson

• Abbvie Inc.

• Merck & Co. Inc.

• Bristol-Myers Squibb Company

• Amgen Inc.

• Eli Lilly and Company

• Gilead Sciences Inc.

• Regeneron Pharmaceuticals Inc.

• Biogen Inc.

• Others

Key Developments

The market has undergone significant developments as industry participants seek to expand capabilities and enhance product portfolios.

• In February 2025: Zydus lifesciences launched VaxiFlu-4, the first quadrivalent flu vaccine in India. The formula is WHO based and targets emerging strains of influenza, and it is a breakthrough in terms of vaccine technology.

• In January 2025: Lecanemab (Leqembi) has been approved to treat Alzheimer's by the U.S. FDA to be used on an accelerated basis. The medication decreases the amyloid-β scars and has a slight impact on slowing cognitive deterioration in the initial phase patients, a novel in neurodegenerative medication development.

These strategic activities have allowed companies to strengthen market positions, expand product offerings, enhance technological capabilities, and capitalize on growth opportunities within the expanding market.

The US Biopharmaceuticals Market is segmented as follows:

By Product Type

• Monoclonal Antibodies

o   Naked Monoclonal Antibodies

o   Antibody-Drug Conjugates

o   Bispecific Antibodies

• Recombinant Proteins

o   Recombinant Hormones

o   Recombinant Growth Factors

o   Recombinant Enzymes

• Vaccines

o   Recombinant Vaccines

o   Conjugate Vaccines

o   Live Attenuated Vaccines

• Cell and Gene Therapies

o   CAR T-Cell Therapies

o   Gene Therapies

o   Stem Cell Therapies

• Other Products

By Therapeutic Application

• Oncology

• Autoimmune Disorders

• Infectious Diseases

• Metabolic Disorders

• Cardiovascular Diseases

• Neurological Disorders

• Other Applications

By Drug Type

• Proprietary Branded Drugs

• Biosimilars

• Generic Biologics

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies